Kyntra Bio to report Q1 2026 financial results and host investor call on May 11

Kyntra Bio will announce its first quarter 2026 financial results on May 11 after market close, followed by a conference call at 5:00 PM Eastern Time to discuss the company's performance and business updates. The biopharmaceutical company focuses on oncology and rare disease therapies, with products like Roxadustat approved for anemia in chronic kidney disease and ongoing trials for cancer treatments. Investors can access the webcast live or via replay on Kyntra Bio's website. This update is important for stakeholders tracking the company's progress in drug development and market expansion.